RNASET2 and neoplasm: To corroborate our results showing an in vivo Rnaset2-mediated rebalance of M1/M2 macrophages ratio, we conducted a flow cytometric assay on day 17 after tumor injection on tumor-infiltrating leukocytes in the three groups of C51 tumor model.